Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income (2020 - 2025)

Historic Net Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' Net Income rose 1825.38% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 12479.84%. This contributed to the annual value of -$61.0 million for FY2024, which is 198615.86% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Net Income stood at -$11.0 million for Q3 2025, which was up 1825.38% from -$9.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Net Income's 5-year high stood at -$2.9 million during Q1 2023, with a 5-year trough of -$35.7 million in Q4 2021.
  • Over the past 5 years, Insight Molecular Diagnostics' median Net Income value was -$10.1 million (recorded in 2022), while the average stood at -$13.5 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 43856.95% in 2021, then skyrocketed by 7156.74% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Income (Quarter) stood at -$35.7 million in 2021, then rose by 7.65% to -$33.0 million in 2022, then soared by 91.12% to -$2.9 million in 2023, then crashed by 1049.25% to -$33.6 million in 2024, then skyrocketed by 67.15% to -$11.0 million in 2025.
  • Its last three reported values are -$11.0 million in Q3 2025, -$9.8 million for Q2 2025, and -$6.8 million during Q1 2025.